Wireless Capsule
Endoscopy at Penn
November/December 2007
Medieval geographers once marked
mysterious regions beyond the known
world with the words “terra incognita,” a
phrase used to describe places unknown.
Until recently, the small bowel was one
such place, its deep and tortuous folds
hidden to most diagnostic methods. With
the advent of capsule endoscopy, however,
the mysteries of the small bowel are
currently disappearing at the rate of 120
images a minute.
Originating in the 1980s, the premise
of a tiny, ingestible capsule containing
a camera preceded miniaturization
technology by almost two decades, a time
during which enteroclysis and push
enteroscopy came into use for small bowel
investigation.
Capsule endoscopy (CE)
was introduced in 2001 as an adjunctive
tool for the evaluation of small intestinal
diseases and disorders, and has since
become the procedure of choice for
evaluation of the small bowel mucosa. Contained in a indigestible
plastic shell, current capsule endoscopes are
approximately 11 mm in diameter
and 26 mm in length. The capsule's
miniature imaging system is comprised
of a metal oxide silicon chip camera,
six light emitting diodes, two silver
oxide batteries and a UHF-band radio
telemetry transmitter.
Inside the Pillcam |

- Optical dome
- Lens holder
- Lens
- Illuminating LEDs (Light Emitting Diode)
- CMOS (Complementary Metal Oxide Semiconductor)
imager
- Battery
- ASIC (Application Specific Integrated
Circuit) transmitter
- Antenna
|
|
Patients wear an
abdominal sensor array and an
external data recorder unit capable of
processing two images a second. The
capsule is swallowed with a glass of
water after the patient has fasted for
12 hours and travels through the GI
system by natural peristalsis. The
capsule is disposable and is excreted
naturally. Acquired images have a 1:8
magnification, which is higher than
that of conventional endoscopes.
Capsule Endoscopy at Penn
Gastroenterologists David
Jaffe, MD, and Nuzhat
Ahmad, MD,
currently employ capsule endoscopy at
the Penn Digestive & Liver Center as
an adjunctive diagnostic modality
for obscure gastrointestinal bleeding
when endoscopy and colonoscopy are
unrevealing.
“Capsule endoscopy
is a giant step forward in the visualization
of small bowel mucosa. It enables us to identify
diseases and conditions that may not be readily
identifiable using conventional endoscopy
and radiology.”
– Nuzhat Ahmad, MD
Associate Director, Endoscopic Services,
Hospital of the University of Pennsylvania |
|
“In the presence of
bleeding following negative upper
endoscopy and colonoscopy, capsule
endoscopy can often preclude a more
invasive diagnostic procedure,” says
Dr. Jaffe. CE is also used at Penn in
patients with suspected Crohn’s
disease, and in selected patients with suspected small bowel
disease in whom
other imaging studies are equivocal.
Clinical Studies
Efficacy studies of CE indicate
that the technology demonstrates a
substantial diagnostic yield in about
two-thirds or more of patients. A meta-analysis
of comparative studies performed
in 2006 found CE to be comparable to
intraoperative endoscopy and superior
to push enteroscopy and small bowel
radiography for diagnosing small bowel
pathology in patients with obscure
gastrointestinal bleeding.
In this study,
CE was also found to be superior
to colonoscopy with ileoscopy, CT
enterography, and push enteroscopy for
diagnosing nonstricturing small bowel
Crohn's disease.
Issues
Many of the concerns linked to
first-generation capsule endoscopes
have been resolved by improved practice
standards and clinical trial findings.
At one time, for example, the risks
identified with CE included delayed
transit in patients with gastroparesis – a
concern now addressed by endoscopically
placing the capsule beyond the stomach.
Other complications,
including small bowel obstruction and pseudoobstruction
(~1% incidence in published
series) are now typically ruled out by
X-ray prior to the procedure. Contraindications to capsule
endoscopy include dementia, esophageal stricture,
swallowing disorders, small bowel
obstruction and defibrillators or
pacemakers.
The Future
The FDA recently approved CE
for screening and diagnosing patients
with esophagitis and Barrett's
esophagus. Its exact role in clinical
practice remains to be determined.
Investigations of CE technology for
the diagnosis of small bowel lesions
and celiac disease are currently under
way. With anticipated advances in
technology, the development of a
capsule capable of evaluating the
colon may also be on the horizon.
|

|
Referring Physicians: To speak with a Penn physician
or refer a patient, contact PennHealth through the secure online
referral form or by calling
1-800-789-PENN
(7366). |
 |
 |
 |
|